Caris life sciences announces new study demonstrating the power and clinical utility of its caris assure® blood-based assay for multi-cancer early detection, minimal residual disease and therapy selection

Scientific reports study validates the first multifunctional, ai-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. irving, texas , july 8, 2025 /prnewswire/ -- caris life sciences ® (nasdaq: cai), a leading, patient-centric, next-generation ai techbio company and precision medicine pioneer, announced a landmark study published in scientific reports, a nature journal, demonstrating the accuracy and clinical utility of the caris assure® blood-based biopsy assay across the cancer continuum.
CAI Ratings Summary
CAI Quant Ranking